Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
Summary: Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits in vitro activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses, inhibiting exp...
Сохранить в:
| Главный автор: | |
|---|---|
| Формат: | |
| Опубликовано: |
Elsevier,
2016-05-01T00:00:00Z.
|
| Предметы: | |
| Online-ссылка: | Connect to this object online. |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_8d7bc7c7794541b0b08c44aef817d3d7 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Jean-François Rossignol |e author |
| 245 | 0 | 0 | |a Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus |
| 260 | |b Elsevier, |c 2016-05-01T00:00:00Z. | ||
| 500 | |a 1876-0341 | ||
| 500 | |a 10.1016/j.jiph.2016.04.001 | ||
| 520 | |a Summary: Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits in vitro activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses, inhibiting expression of the viral N protein. Nitazoxanide also suppresses production of pro-inflammatory cytokines in peripheral blood mononuclear cells and suppresses interleukin 6 production in mice. Having been used extensively in clinical trials and in post-marketing experience, nitazoxanide is an attractive drug candidate for treatment of Middle East respiratory syndrome. Future research should include in vitro mechanism studies, animal models of MERS-CoV infection, clinical trials, including dose-ranging trials, and evaluation of combination therapy with other potential MERS-CoV antivirals. Keywords: Nitazoxanide, Coronavirus, MERS-CoV, Treatment | ||
| 546 | |a EN | ||
| 690 | |a Infectious and parasitic diseases | ||
| 690 | |a RC109-216 | ||
| 690 | |a Public aspects of medicine | ||
| 690 | |a RA1-1270 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Journal of Infection and Public Health, Vol 9, Iss 3, Pp 227-230 (2016) | |
| 787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S1876034116300181 | |
| 787 | 0 | |n https://doaj.org/toc/1876-0341 | |
| 856 | 4 | 1 | |u https://doaj.org/article/8d7bc7c7794541b0b08c44aef817d3d7 |z Connect to this object online. |